MCM
XLRN

Mazama Capital Management’s Acceleron Pharma XLRN Stock Holding History

Mazama Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-20,000
Closed -$445K – 288
2013
Q3 		$445K Buy
+20,000
New +$431K 0.24% 126

Other funds holding XLRN

PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Mazama Capital Management's XLRN Position: Q4 2013 in Review

Mazama Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2013, closing a stake of 20,000 shares — an estimated $445K sold.

Mazama Capital Management first reported a position in XLRN in Q3 2013 and held it in 1 quarter. The position peaked at $445K in Q3 2013. 62 funds tracked by Wall St. Rank hold XLRN as of Q4 2013.

  • Mazama Capital Management reported no remaining Acceleron Pharma position as of Q4 2013 after selling out during the quarter.
  • Mazama Capital Management sold 20,000 Acceleron Pharma shares in Q4 2013, an estimated $445K.
  • Mazama Capital Management first reported a position in Acceleron Pharma in Q3 2013 and held it in 1 quarter.
  • Mazama Capital Management's Acceleron Pharma position peaked at $445K in Q3 2013.
  • 62 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2013.

Based on Mazama Capital Management's 13F filing for Q4 2013, filed 10 Feb 2014.